Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Eslicarbazepine acetate and methods of use

A technology of eslicarbazepine acetate and drugs, which is applied in the direction of pharmaceutical formulas, medical preparations of non-active ingredients, digestive system, etc., and can solve problems such as side effects and reduced efficacy of oxcarbazepine

Inactive Publication Date: 2008-07-09
BIAL PORTELA & CA SA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, treatment with carbamazepine may cause serious side effects due to the production of toxic metabolites
Oxcarbazepine was developed to reduce the severity of those side effects, but oxcarbazepine has greatly reduced potency

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eslicarbazepine acetate and methods of use
  • Eslicarbazepine acetate and methods of use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0015] The foregoing and following aspects and embodiments, including the studies discussed herein, have been described and illustrated by way of illustration only and should not be construed as limitations on scope.

[0016] One aspect of the present disclosure pertains to a method of treating at least one disease or condition in a patient in need thereof by administering a pharmaceutical composition comprising a pharmacologically effective amount of eslicarbazepine acetate.

[0017] In an exemplary embodiment of the present disclosure, the pharmaceutical composition comprising eslicarbazepine acetate is administered in a once-daily dosing regimen.

[0018] In another exemplary embodiment of the present disclosure, by exposure rate and exposure degree (C max and AUC 0-τ ) as a standard, the pharmaceutical composition is administered at a dose expected to maximize the total exposure to eslicarbazepine.

[0019] In an exemplary embodiment of the present disclosure, the at lea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to the treatment of various diseases and conditions like affective disorders, schizoaffective disorders, bipolar disorders, attention disorders, anxiety disorders, neuropathic pain and neuropathic pain-related disorders, sensorimotor disorders, vestibular disorders, or nervous function alternations in degenerative and post-ischemic diseases, etc , with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.

Description

technical field [0001] The present disclosure relates to pharmaceutical compositions and methods of treatment using eslicarbazepine acetate. Background technique [0002] Carbamazepine is commonly used to treat epilepsy, pain disorders such as trigeminal neuralgia, and affective brain disorders such as bipolar disorder. However, treatment with carbamazepine may cause serious side effects due to the production of toxic metabolites. Oxcarbazepine was developed to reduce the severity of those side effects, but oxcarbazepine has greatly reduced potency. See, e.g., Almeida, L. & Soares-da-Silva, P. "Safety, Tolerability, and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic, in a Rising Multiple-Dose Study in Young Healthy Humans," J. Clin. Pharmacol. 44, 906-918 (2004) (referred to herein as "Almeida I"). [0003] Therefore, there is a need for pharmaceutical compositions and methods with high efficacy and low incidence of side effects to treat various cond...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/55A61P25/22A61P25/28A61P25/04A61P25/24A61P25/30A61P25/16A61P25/06A61P25/02A61P25/18A61P25/14A61P27/16A61P25/20A61P25/00A61P25/32
CPCA61K31/55A61P1/08A61P1/14A61P3/04A61P5/24A61P15/00A61P25/00A61P25/02A61P25/04A61P25/06A61P25/08A61P25/14A61P25/16A61P25/18A61P25/20A61P25/22A61P25/24A61P25/28A61P25/30A61P25/32A61P25/36A61P27/16A61P29/00A61K47/00
Inventor P·M·维埃拉阿劳若苏亚雷斯达席尔瓦J·L·德阿尔梅达
Owner BIAL PORTELA & CA SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com